Mesa Laboratories/$MLAB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Mesa Laboratories

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

Ticker

$MLAB
Primary listing

Industry

Life Sciences Tools & Services

Employees

730

ISIN

US59064R1095

MLAB Metrics

BasicAdvanced
$507M
-
-$0.36
0.97
$0.64
0.69%

What the Analysts think about MLAB

Analyst ratings (Buy, Hold, Sell) for Mesa Laboratories stock.

Bulls say / Bears say

Mesa Laboratories reported a 17.5% increase in revenue for Q3 2025, reaching $62.84 million, indicating strong growth across key divisions. (nasdaq.com)
The Biopharmaceutical Development division showed the strongest core organic growth at 31.3% in Q3 2025, highlighting its potential as a significant revenue driver. (stocktitan.net)
Mesa Labs repaid $9.4 million in debt during Q3 2025, reducing their Total Net Leverage Ratio to 3.20x, demonstrating a commitment to strengthening their financial position. (nasdaq.com)
Despite strong operational performance, Mesa Labs reported a net loss in Q3 2025, primarily due to unrealized foreign currency losses and interest expenses, which could impact investor confidence. (stocktitan.net)
The Clinical Genomics division faced headwinds in China and North America, potentially affecting overall revenue growth and market expansion. (stocktitan.net)
Mesa Laboratories has a net cash position of -$179.32 million, indicating a significant level of debt that may pose financial risks. (stockanalysis.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.

MLAB Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MLAB Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MLAB

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs